30th August 2018

Biocatalysts plan £6m investment following acquisition

Specialist biotechnology company Biocatalysts, which was recently acquired by Brain AG, is investing £6m in expanding its manufacturing capacity.

The company, which manufactures enzymes, has extended its existing building by 11,000 sq ft and now plans to fit the space out with new software-controlled equipment, including a 10,000L fermenter and down-stream processing machinery.

The new production area will also give the company space to expand its capacity further in future.

Daren Bryce, commercial director at Biocatalysts, said: “This represents a very exciting time in the speciality enzyme field.

“The unique breadth of offering that Biocatalysts has, from discovery right through to large scale production, will allow previously in-accessible novel enzymes at commercial scale to our customers.”

View Biocatalysts profile here.